RLAY
Price
$4.46
Change
+$0.14 (+3.24%)
Updated
Jan 17 closing price
Capitalization
746.53M
33 days until earnings call
SABS
Price
$3.53
Change
-$0.03 (-0.84%)
Updated
Jan 17 closing price
Capitalization
32.58M
Ad is loading...

RLAY vs SABS

Header iconRLAY vs SABS Comparison
Open Charts RLAY vs SABSBanner chart's image
Relay Therapeutics
Price$4.46
Change+$0.14 (+3.24%)
Volume$3.39M
Capitalization746.53M
SAB Biotherapeutics
Price$3.53
Change-$0.03 (-0.84%)
Volume$77.94K
Capitalization32.58M
RLAY vs SABS Comparison Chart
Loading...
RLAY
Daily Signalchanged days ago
Gain/Loss if bought
Show more...
SABS
Daily Signalchanged days ago
Gain/Loss if bought
Show more...
View a ticker or compare two or three
VS
RLAY vs. SABS commentary
Jan 19, 2025

To compare these two companies we present long-term analysis, their fundamental ratings and make comparative short-term technical analysis which are presented below. The conclusion is RLAY is a Hold and SABS is a Hold.

Ad is loading...
COMPARISON
Comparison
Jan 19, 2025
Stock price -- (RLAY: $4.46 vs. SABS: $3.53)
Brand notoriety: RLAY and SABS are both not notable
Both companies represent the Biotechnology industry
Current volume relative to the 65-day Moving Average: RLAY: 128% vs. SABS: 101%
Market capitalization -- RLAY: $746.53M vs. SABS: $32.58M
RLAY [@Biotechnology] is valued at $746.53M. SABS’s [@Biotechnology] market capitalization is $32.58M. The market cap for tickers in the [@Biotechnology] industry ranges from $368.92B to $0. The average market capitalization across the [@Biotechnology] industry is $2.37B.

Long-Term Analysis

It is best to consider a long-term outlook for a ticker by using Fundamental Analysis (FA) ratings. The rating of 1 to 100, where 1 is best and 100 is worst, is divided into thirds. The first third (a green rating of 1-33) indicates that the ticker is undervalued; the second third (a grey number between 34 and 66) means that the ticker is valued fairly; and the last third (red number of 67 to 100) reflects that the ticker is undervalued. We use an FA Score to show how many ratings show the ticker to be undervalued (green) or overvalued (red).

RLAY’s FA Score shows that 1 FA rating(s) are green whileSABS’s FA Score has 0 green FA rating(s).

  • RLAY’s FA Score: 1 green, 4 red.
  • SABS’s FA Score: 0 green, 5 red.
According to our system of comparison, SABS is a better buy in the long-term than RLAY.

Short-Term Analysis

It is best to consider a short-term outlook for a ticker by using Technical Analysis (TA) indicators. We use Odds of Success as the percentage of outcomes which confirm successful trade signals in the past.

If the Odds of Success (the likelihood of the continuation of a trend) for each indicator are greater than 50%, then the generated signal is confirmed. A green percentage from 90% to 51% indicates that the ticker is in a bullish trend. A red percentage from 90% - 51% indicates that the ticker is in a bearish trend. All grey percentages are below 50% and are considered not to confirm the trend signal.

RLAY’s TA Score shows that 2 TA indicator(s) are bullish while SABS’s TA Score has 3 bullish TA indicator(s).

  • RLAY’s TA Score: 2 bullish, 4 bearish.
  • SABS’s TA Score: 3 bullish, 3 bearish.
According to our system of comparison, SABS is a better buy in the short-term than RLAY.

Price Growth

RLAY (@Biotechnology) experienced а +0.22% price change this week, while SABS (@Biotechnology) price change was -8.07% for the same time period.

The average weekly price growth across all stocks in the @Biotechnology industry was -1.44%. For the same industry, the average monthly price growth was +2.66%, and the average quarterly price growth was -1.92%.

Reported Earning Dates

RLAY is expected to report earnings on May 01, 2025.

SABS is expected to report earnings on May 09, 2024.

Industries' Descriptions

@Biotechnology (-1.44% weekly)

Biotechnology involves genetic or protein engineering to produce medicines/therapies for treating and preventing ailments. The industry also provides crucial ingredients for diagnostics. This multi-billion-dollar industry is heavily focused on research and development, as companies attempt to continually come up with cutting-edge solutions for health. New discoveries for the treatment of diseases provide opportunities for growth for a company in this industry. Discoveries, however, must pass the regulatory approval from the U.S. Food and Drug Administration (FDA) before they can make it to markets. Amgen Inc., Gilead Sciences, Inc. and Celgene Corporation are examples of companies in this industry.

SUMMARIES
Loading...
FUNDAMENTALS
Fundamentals
RLAY($747M) has a higher market cap than SABS($32.6M). RLAY YTD gains are higher at: 8.252 vs. SABS (-6.963). SABS has higher annual earnings (EBITDA): -40.29M vs. RLAY (-389.45M). RLAY has more cash in the bank: 840M vs. SABS (30.4M). SABS has less debt than RLAY: SABS (4.52M) vs RLAY (49.8M). RLAY has higher revenues than SABS: RLAY (10M) vs SABS (0).
RLAYSABSRLAY / SABS
Capitalization747M32.6M2,291%
EBITDA-389.45M-40.29M967%
Gain YTD8.252-6.963-119%
P/E RatioN/AN/A-
Revenue10M0-
Total Cash840M30.4M2,763%
Total Debt49.8M4.52M1,102%
TECHNICAL ANALYSIS
Technical Analysis
RLAYSABS
RSI
ODDS (%)
N/A
N/A
Stochastic
ODDS (%)
Bearish Trend 11 days ago
87%
Bullish Trend 11 days ago
82%
Momentum
ODDS (%)
Bullish Trend 11 days ago
80%
Bearish Trend 11 days ago
73%
MACD
ODDS (%)
N/A
Bearish Trend 11 days ago
83%
TrendWeek
ODDS (%)
Bullish Trend 11 days ago
77%
Bullish Trend 11 days ago
62%
TrendMonth
ODDS (%)
Bullish Trend 11 days ago
74%
Bullish Trend 11 days ago
64%
Advances
ODDS (%)
Bullish Trend 11 days ago
81%
Bullish Trend 11 days ago
68%
Declines
ODDS (%)
Bearish Trend 19 days ago
90%
Bearish Trend 13 days ago
87%
BollingerBands
ODDS (%)
Bearish Trend 11 days ago
90%
N/A
Aroon
ODDS (%)
Bearish Trend 11 days ago
83%
N/A
View a ticker or compare two or three
Ad is loading...
RLAY
Daily Signalchanged days ago
Gain/Loss if bought
Show more...
SABS
Daily Signalchanged days ago
Gain/Loss if bought
Show more...
Interesting Tickers
1D
1W
1M
1Q
6M
1Y
5Y
1 Day
STOCK / NAMEPrice $Chg $Chg %
PRDO27.670.34
+1.24%
Perdoceo Education Corp
WAB201.692.34
+1.17%
Wabtec
TCBX33.100.34
+1.04%
Third Coast Bancshares
NMTC1.050.01
+0.95%
NeuroOne Medical Technologies Corp
WTM1852.32-9.68
-0.52%
White Mountains Insurance Group Ltd

RLAY and

Correlation & Price change

A.I.dvisor indicates that over the last year, RLAY has been loosely correlated with XNCR. These tickers have moved in lockstep 50% of the time. This A.I.-generated data suggests there is some statistical probability that if RLAY jumps, then XNCR could also see price increases.

1D
1W
1M
1Q
6M
1Y
5Y
Ticker /
NAME
Correlation
To RLAY
1D Price
Change %
RLAY100%
+3.24%
XNCR - RLAY
50%
Loosely correlated
-3.94%
VCYT - RLAY
44%
Loosely correlated
-1.27%
RXRX - RLAY
43%
Loosely correlated
+2.03%
AXON - RLAY
42%
Loosely correlated
+1.37%
FHTX - RLAY
42%
Loosely correlated
+2.62%
More

SABS and

Correlation & Price change

A.I.dvisor tells us that SABS and HOOK have been poorly correlated (+30% of the time) for the last year. This A.I.-generated data suggests there is low statistical probability that SABS and HOOK's prices will move in lockstep.

1D
1W
1M
1Q
6M
1Y
5Y
Ticker /
NAME
Correlation
To SABS
1D Price
Change %
SABS100%
-0.84%
HOOK - SABS
30%
Poorly correlated
+0.52%
RLAY - SABS
27%
Poorly correlated
+3.24%
ENTA - SABS
25%
Poorly correlated
+8.25%
ZNTL - SABS
25%
Poorly correlated
-6.28%
NKTX - SABS
25%
Poorly correlated
-0.80%
More